

Baylor Scott & White Health Plan

BSW SeniorCare HMO-POS BSW SeniorCare PPO Covenant Health Advantage HMO

2025 Medicare Part B Drugs Requiring Step Therapy

Medicare Part B Step Therapy

- Some medically administered Part B medications, like injectable drugs or biologics, may have special requirements or coverage limits, such as step therapy.
- Step therapy requires a trial of a preferred drug to treat a medical condition before covering a non-preferred drug.
- The step therapy requirement does not apply to members who have already received treatment with a non-preferred drug within the past 365 days.
- Both preferred and non-preferred drugs may still be subject to prior authorization.
- This list will be updated as additional drugs are added to the Part B drug Step Therapy program.

Drug or Drug Class	Preferred Part B Drug(s) -	NON-Preferred Part B Drug(s)	Effective
	No Step Therapy Required	-Step Therapy Required	Date
Trastuzumab	Trazimera	Herceptin	1/1/2025
	Kanjinti	Herceptin Hylecta	
	Ogivri		
	Ontruzant		
	Herzuma		
Bevacizumab	Mvasi	Avastin	1/1/2025
(oncology use)	Zirabev	Alymsys	
		Avzivi	
		Vegzelma	
Colony Stimulating	Neulasta	Fulphilia	1/1/2025
Agents (long acting)	Udenyca	Fylnetra	
		Nyvepria	
		Stimufend	
		Ziextenzo	
Rituximab	Ruxience	Rituxan	1/1/2025
	Truxima	Rituxan Hycela	
		Riabni	
Colony Stimulating	Zarxio	Neupogen	1/1/2025
Agents (short acting)		Nivestym	
		Releuko	
		Granix	
Vascular Endothelial	Avastin	Beovu	5/1/2025
Growth Factor		Byooviz	
(VEGF) Inhibitors –		Eylea	
For ophthalmic		Eylea HD	
indications only		Lucentis	
		Susvimo	
		Vabysmo	

Bendamustine	Belrapzo Bendeka Bendamustine (brand Treanda)	Bendamustine 505b2 formulations Vivimusta	1/1/2025
Bone antiresorptive therapy (oncology use; does not apply to prostate or breast cancer)	Zoledronic acid	Xgeva	1/1/2025
Taxane therapy (does not apply to pancreatic cancer, ampullary adenocarcinoma, biliary tract cancers)	Paclitaxel (brand Taxol) Docetaxel (brand Taxotere)	Docetaxel 505b2 formulations Paclitaxel Protein-Bound (brand Abraxane) Paclitaxel Protein-Bound 505b2 formulations	1/1/2025